✦ LIBER ✦

Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer

✍ Scribed by Hoyle, Martin; Peters, Jaime; Crathorne, Louise; Jones-Hughes, Tracey; Cooper, Chris; Napier, Mark; Hyde, Chris

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Quality of life analysis in patients wit

✍ Láng, István; Köhne, Claus-Henning; Folprecht, Gunnar; Rougier, Philippe; Curran 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 325 KB

Sensitivity to previous irinotecan treat

✍ Kohei Shitara; Takashi Ura; Keitaro Matsuo; Daisuke Takahari; Tomoya Yokota; Sat 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 228 KB

Economic analysis of bevacizumab, cetuxi

✍ Lawrence, Donna; Maschio, Michael; Leahy, Kevin J.; Yunger, Simon; Easaw, Jacob 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 466 KB

Biweekly cetuximab plus FOLFIRI/irinotec

✍ Chen, Ye; Cao, Dan; Bi, Feng; Li, Qiu; Qiu, Meng 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 222 KB

Panitumumab – an effective long-term tre

✍ Elena Elez; Maria Alsina; Josep Tabernero 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 202 KB

PCN64 The Cost Effectiveness of Cetuxima

✍ Chaugule, S.; Hay, J. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB